

Donna E Hogge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4888057/publications.pdf>

Version: 2024-02-01

135
papers

6,867
citations

66234

42
h-index

62479

80
g-index

135
all docs

135
docs citations

135
times ranked

7699
citing authors

#	ARTICLE	IF	CITATIONS
1	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. <i>Blood Advances</i> , 2021, 5, 1719-1728.	2.5	13
2	A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 2474.	5.8	49
3	CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e481-e491.	2.2	92
4	Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 631-640.	0.6	15
5	Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada. <i>EJHaem</i> , 2020, 1, 69-78.	0.4	1
6	Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e427-e436.	0.2	0
7	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 984-997.	5.1	330
8	Health state utilities associated with treatment options for acute myeloid leukemia (AML). <i>Journal of Medical Economics</i> , 2019, 22, 567-576.	1.0	6
9	Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 784-790.	0.2	13
10	Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1209-1215.	2.0	14
11	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2684-2692.	0.8	682
12	Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e481-e491.	0.2	11
13	Excellent real-world outcomes of adults with Burkitt lymphoma treated with <sc>CODOX</sc> + <sc>IVAC</sc> plus or minus rituximab. <i>British Journal of Haematology</i> , 2018, 181, 782-790.	1.2	15
14	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. <i>Blood</i> , 2018, 132, 563-563.	0.6	26
15	Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 909-915.	0.6	5
16	Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML). <i>Journal of Clinical Oncology</i> , 2017, 35, 7036-7036.	0.8	3
17	Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples. <i>Analytical Chemistry</i> , 2016, 88, 5680-5688.	3.2	35
18	Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 526-535.	1.2	10

#	ARTICLE	IF	CITATIONS
19	An Integrated Analysis of Heterogeneous Drug Responses in Acute Myeloid Leukemia That Enables the Discovery of Predictive Biomarkers. <i>Cancer Research</i> , 2016, 76, 1214-1224.	0.4	16
20	Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia. <i>Blood</i> , 2016, 128, 5852-5852.	0.6	0
21	Identification of prognostic subgroups among acute myeloid leukemia patients with intermediate risk cytogenetics using a flow-cytometry-based assessment of ABC-transporter function. <i>Leukemia Research</i> , 2015, 39, 689-695.	0.4	6
22	Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 341-348.	0.2	39
23	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 1025-1036.	5.1	129
24	MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. <i>Experimental Hematology</i> , 2015, 43, 858-868.e7.	0.2	28
25	Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. <i>Cancer</i> , 2015, 121, 234-242.	2.0	144
26	Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1437-1444.	2.0	24
27	Deep profiling of multitube flow cytometry data. <i>Bioinformatics</i> , 2015, 31, 1623-1631.	1.8	13
28	Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O ⁶ -methylguanine DNA methyltransferase expression. <i>British Journal of Haematology</i> , 2014, 167, 664-670.	1.2	14
29	Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. <i>American Journal of Hematology</i> , 2014, 89, 363-368.	2.0	79
30	Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. <i>Blood</i> , 2014, 123, 3239-3246.	0.6	298
31	Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110 γ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors. <i>Leukemia Research</i> , 2013, 37, 697-704.	0.4	11
32	Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies. <i>BMC Genomics</i> , 2013, 14, 550.	1.2	12
33	Single-Nucleotide Polymorphisms in Reductase Genes Are not Associated with Response to Daunorubicin-Based Remission Induction. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1918-1920.	1.1	4
34	Expression of Integrin α 2 Receptor in Human Cord Blood CD34 ⁺ CD38 ⁺ CD90 ⁺ Stem Cells Engrafting Long-Term in NOD/SCID-IL2R β ³ null Mice. <i>Stem Cells</i> , 2013, 31, 360-371.	1.4	7
35	A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. <i>Frontiers in Genetics</i> , 2013, 4, 231.	1.1	57
36	AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin. <i>PLoS ONE</i> , 2013, 8, e53518.	1.1	39

#	ARTICLE	IF	CITATIONS
37	An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2013, 122, 2682-2682.	0.6	7
38	Single-Nucleotide Polymorphisms in <i>Aldo-Keto</i> and <i>Carbonyl Reductase</i> Genes Are Not Associated with Acute Cardiotoxicity after Daunorubicin Chemotherapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 2118-2120.	1.1	22
39	Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1543-1551.	0.6	16
40	Distinct but phenotypically heterogeneous human cell populations produce rapid recovery of platelets and neutrophils after transplantation. <i>Blood</i> , 2012, 119, 3431-3439.	0.6	23
41	Selective small molecule inhibitors of p110 α and β isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors. <i>Experimental Hematology</i> , 2012, 40, 922-933.	0.2	7
42	Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by Flow Cytometry Is Associated With NPM1 and FLT3 Mutation Status in Cytogenetically Normal Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 274-279.	0.2	20
43	Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 1321-1326.	0.6	19
44	Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2012, 82B, 283-294.	0.7	13
45	Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. <i>Leukemia Research</i> , 2012, 36, 900-904.	0.4	11
46	Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. <i>British Journal of Haematology</i> , 2012, 158, 174-185.	1.2	23
47	Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy. <i>Blood</i> , 2012, 120, 1372-1372.	0.6	3
48	SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. <i>Blood</i> , 2012, 120, 3625-3625.	0.6	10
49	CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors. <i>Blood</i> , 2012, 120, 3626-3626.	0.6	3
50	Cryopreserved mobilized autologous blood progenitors stored for more than 2 years successfully support blood count recovery after high-dose chemotherapy. <i>Cytotherapy</i> , 2011, 13, 856-863.	0.3	9
51	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350) Tj ETQq1 1 0.784314 rgBT ₃₂ /Overl	2.0	32
52	Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. <i>Experimental Hematology</i> , 2011, 39, 741-750.	0.2	74
53	Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). <i>Leukemia and Lymphoma</i> , 2011, 52, 34-41.	0.6	45
54	Wnt Inhibitor Screen Reveals Iron Dependence of β -Catenin Signaling in Cancers. <i>Cancer Research</i> , 2011, 71, 7628-7639.	0.4	115

#	ARTICLE	IF	CITATIONS
55	Selective Small Molecule Inhibition of P110 α and β Isoforms of PI3 Kinase Is Cytotoxic to Human AML Progenitors. <i>Blood</i> , 2011, 118, 1556-1556.	0.6	0
56	Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease. <i>Blood</i> , 2010, 116, 4859-4869.	0.6	40
57	Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials. <i>Biologicals</i> , 2010, 38, 144-149.	0.5	7
58	A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. <i>Leukemia Research</i> , 2010, 34, 1035-1042.	0.4	15
59	Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. <i>Leukemia Research</i> , 2010, 34, 1358-1365.	0.4	27
60	Identification of miR-145 and miR-146a as mediators of the 5q Δ syndrome phenotype. <i>Nature Medicine</i> , 2010, 16, 49-58.	15.2	588
61	Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 639-646.	2.0	30
62	Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. <i>Blood</i> , 2010, 116, 3298-3298.	0.6	3
63	Mir-223 Is Dispensable for the Onset of Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 501-501.	0.6	2
64	Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60-75. <i>Blood</i> , 2010, 116, 655-655.	0.6	10
65	Novel Photodepletion Strategy to Preserve and Expand Tregs While Eliminating CD4+ Effector T Cells From Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2010, 116, 353-353.	0.6	0
66	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. <i>Blood</i> , 2010, 116, 3523-3523.	0.6	0
67	Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Eradication of Specific FISH Abnormalities with Relation to Gvhd and Transplant Outcomes.. <i>Blood</i> , 2010, 116, 3465-3465.	0.6	10
68	Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1187-1192.	3.3	168
69	Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells. <i>Experimental Hematology</i> , 2009, 37, 450-460.	0.2	32
70	Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. <i>Leukemia Research</i> , 2009, 33, 271-275.	0.4	74
71	Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia. <i>Leukemia Research</i> , 2009, 33, 1149-1150.	0.4	0
72	IPSS Poor-Risk Karyotype as a Predictor of Outcome for Patients with Myelodysplastic Syndrome following Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 205-213.	2.0	23

#	ARTICLE	IF	CITATIONS
73	Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic Progenitors for Cytarabine: Daunorubicin Delivered as CPX-351 Liposome Injection.. Blood, 2009, 114, 2071-2071.	0.6	3
74	Distinct Signaling Profiles of Gemtuzumab Ozogamicin Responsiveness and Refractoriness in Acute Myeloid Leukemia.. Blood, 2009, 114, 2745-2745.	0.6	0
75	Short Progression Free Survival Post Non-Myeloablative Sibling Allogeneic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2009, 114, 4323-4323.	0.6	0
76	Differential Expression of Mirna* Species in Cancer and the Contribution of MiR-223* to the Development of Acute Myeloid Leukemia.. Blood, 2009, 114, 2960-2960.	0.6	0
77	Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (<12 months).. Blood, 2009, 114, 2872-2872.	0.6	0
78	MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Experimental Hematology, 2008, 36, 433-442.	0.2	87
79	Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leukemia and Lymphoma, 2008, 49, 543-553.	0.6	138
80	Impact of Comorbidity Index on Outcome with Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Blood, 2008, 112, 3305-3305.	0.6	0
81	Long-Term Outcome of Myeloablative Allogeneic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2007, 13, 925-931.	2.0	44
82	Early Stem Cell Transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2006, 12, 480-489.	2.0	15
83	Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood, 2006, 108, 88-96.	0.6	226
84	Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood, 2006, 108, 3530-3537.	0.6	55
85	Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma*. British Journal of Haematology, 2006, 133, 634-637.	1.2	27
86	Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genetics and Cytogenetics, 2006, 170, 16-23.	1.0	32
87	Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors.. Clinical Cancer Research, 2006, 12, 1284-1291.	3.2	39
88	High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood, 2005, 106, 1473-1478.	0.6	112
89	Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma*. British Journal of Haematology, 2005, 131, 223-230.	1.2	78
90	Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leukemia and Lymphoma, 2005, 46, 525-531.	0.6	3

#	ARTICLE	IF	CITATIONS
91	High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2005, 23, 7994-8002.	0.8	62
92	Long-Term Follow-Up Results of Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL)-The Vancouver Experience.. <i>Blood</i> , 2005, 106, 4578-4578.	0.6	0
93	Second Solid Cancers after Allogeneic Stem Cell Transplantation: The Vancouver Experience.. <i>Blood</i> , 2005, 106, 1120-1120.	0.6	0
94	Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 2004, 127, 311-321.	1.2	46
95	Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21). <i>Modern Pathology</i> , 2004, 17, 1211-1216.	2.9	17
96	The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. <i>Leukemia Research</i> , 2004, 28, 1221-1226.	0.4	25
97	Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. <i>Protein Expression and Purification</i> , 2004, 33, 123-133.	0.6	46
98	Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. <i>Blood</i> , 2004, 103, 333-339.	0.6	130
99	High Risk AML Outpatient Management: A Retrospective Analysis of Bacteremia Incidence Following Chemotherapy.. <i>Blood</i> , 2004, 104, 884-884.	0.6	1
100	Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphoblastic Lymphoma (T-LBL) : An Intention to Treat Analysis.. <i>Blood</i> , 2004, 104, 900-900.	0.6	2
101	Acceptable Outcomes for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) for Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2004, 104, 3325-3325.	0.6	0
102	Daclizumab Therapy Improves Outcome in Steroid Refractory Acute Graft Versus Host Disease (aGVHD).. <i>Blood</i> , 2004, 104, 5092-5092.	0.6	0
103	Septicemia in Chemotherapy Induced Neutropenic Acute Myeloid Leukemia (AML) Inpatients and Outpatients: A 5 Year Retrospective Experience.. <i>Blood</i> , 2004, 104, 4525-4525.	0.6	0
104	Risk Stratification in Acute Promyelocytic Leukemia Based on Elevated White Cell Count and Reduced Platelet Count Does Not Identify Subsequent Relapses: A Retrospective Review of 60 Patients.. <i>Blood</i> , 2004, 104, 4522-4522.	0.6	0
105	Acute Myelogenous Leukemia with t(8;21) Identification of a Specific Immunophenotype. <i>Leukemia and Lymphoma</i> , 2003, 44, 1713-1718.	0.6	46
106	Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. <i>Blood</i> , 2003, 101, 4529-4538.	0.6	136
107	Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. <i>Blood</i> , 2003, 102, 3743-3752.	0.6	26
108	Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). <i>Blood</i> , 2003, 101, 3142-3149.	0.6	267

#	ARTICLE	IF	CITATIONS
109	Unfulfilled Promise of Endostatin in a Gene Therapy-Xenotransplant Model of Human Acute Lymphocytic Leukemia. <i>Molecular Therapy</i> , 2002, 5, 352-359.	3.7	58
110	Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. <i>Blood</i> , 2002, 100, 862-868.	0.6	118
111	Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 435-443.	2.0	30
112	Polyclonal normal hematopoietic progenitors in patients with acute myeloid leukemia. <i>Experimental Hematology</i> , 2002, 30, 721-728.	0.2	10
113	Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein. <i>Experimental Hematology</i> , 2002, 30, 1316-1323.	0.2	15
114	A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. <i>Cancer Research</i> , 2002, 62, 1730-6.	0.4	96
115	Immunotherapy of Acute Myeloid Leukemia. <i>Current Pharmaceutical Biotechnology</i> , 2001, 2, 209-215.	0.9	5
116	Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34+CD38 ⁺ progenitor cells from patients with acute myeloid leukemia. <i>Blood</i> , 2001, 97, 3882-3889.	0.6	112
117	Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. <i>Blood</i> , 2001, 97, 2286-2292.	0.6	98
118	Growth Characteristics of Acute Myelogenous Leukemia Progenitors That Initiate Malignant Hematopoiesis in Nonobese Diabetic/Severe Combined Immunodeficient Mice. <i>Blood</i> , 1999, 94, 1761-1772.	0.6	151
119	Retroviral marking of acute myelogenous leukemia progenitors that initiate long-term culture and growth in immunodeficient mice. <i>Experimental Hematology</i> , 1999, 27, 1609-1620.	0.2	18
120	Growth Characteristics of Acute Myelogenous Leukemia Progenitors That Initiate Malignant Hematopoiesis in Nonobese Diabetic/Severe Combined Immunodeficient Mice. <i>Blood</i> , 1999, 94, 1761-1772.	0.6	57
121	Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1998, 92, 1910-1917.	0.6	147
122	Detection and Characterization of Primitive Malignant and Normal Progenitors in Patients With Acute Myelogenous Leukemia Using Long-Term Coculture With Supportive Feeder Layers and Cytokines. <i>Blood</i> , 1997, 90, 2555-2564.	0.6	87
123	Sustained proliferation, multi-lineage differentiation and maintenance of primitive human haemopoietic cells in NOD/SCID mice transplanted with human cord blood. <i>British Journal of Haematology</i> , 1997, 98, 1026-1036.	1.2	109
124	Both cycling and noncycling primitive progenitors continue to be mobilized into the circulation during the leukapheresis of patients pretreated with chemotherapy and G-CSF. <i>British Journal of Haematology</i> , 1997, 99, 394-402.	1.2	12
125	Quantitation and characterization of human megakaryocyte colony-forming cells using a standardized serum-free agarose assay. <i>British Journal of Haematology</i> , 1997, 96, 790-800.	1.2	51
126	The effect of GM-CSF and G-CSF on the growth of human osteosarcoma cells in vitro and in vivo. <i>International Journal of Cancer</i> , 1994, 56, 236-243.	2.3	44

#	ARTICLE	IF	CITATIONS
127	3 Cytokines acting early in human haematopoiesis. Best Practice and Research: Clinical Haematology, 1994, 7, 49-63.	1.1	10
128	Cytogenetics and oncogenes in leukemia. Current Opinion in Oncology, 1994, 6, 3-13.	1.1	7
129	Allografting in chronic myeloid leukemia with cultured marrow: Update of the vancouver study. Stem Cells, 1993, 11, 64-66.	1.4	5
130	Continuous activation of primitive hematopoietic cells in long-term human marrow cultures containing irradiated tumor cells. Journal of Cellular Physiology, 1991, 148, 370-379.	2.0	8
131	Nonclonal hemopoietic progenitors in a G6PD heterozygote with chronic myelogenous leukemia revealed after long-term marrow culture. American Journal of Hematology, 1987, 24, 389-394.	2.0	38
132	Juvenile monosomy 7 syndrome: evidence that the disease originates in a pluripotent hemopoietic stem cell. Leukemia Research, 1987, 11, 705-709.	0.4	25
133	Detection of clonal karyotypic abnormalities in most patients with acute nonlymphocytic leukemia examined using short-term culture techniques. Cancer Genetics and Cytogenetics, 1986, 22, 239-251.	1.0	35
134	Promyelocytic blast crisis in chronic granulocytic leukemia with 15;17 translocation. Leukemia Research, 1984, 8, 1019-1023.	0.4	44
135	Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion. American Journal of Hematology, 1983, 14, 363-369.	2.0	93